Other licensed pharmacological options : For patients unsuitable for or unable to tolerate Wegovy, alternatives include: Orlistat (lipase inhibitor that reduces fat absorption) Liraglutide 3mg (another GLP-1 receptor agonist, recommended by NICE TA664 for specific patient groups, though local NHS availability may vary) Consideration of bariatric surgery referral for eligible patients with severe obesity Medically supervised diets : If rapid weight loss is clinically indicated (e.g., pre-bariatric surgery), options include: Very low-calorie diets (800 kcal/day) under specialist supervision for up to 12 weeks Low-calorie diets (8001200 kcal/day) with appropriate nutritional support These differ fundamentally from HCG protocols as they provide adequate protein, vitamins, and minerals and are used within NHS-approved frameworks

Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus
To address this, the FDA offers early regulatory guidance through industry advisories and the pre-ANDA program, streamlining the development and approval processes
For most individuals, this is unlikely to pose problems, but those with compromised immune systems or autoimmune conditions should exercise additional caution and seek medical advice